Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects

• Status: Completed
• Trial end date: 2018-01-29
• Target enrollment: 0
• Participant gender: Male

Summary

A study in healthy male subjects to investigate whether repeated administrations of cimetidine (a medication which decreases the amount of acid in the stomach) can affect the fate in the body (amount and time of presence in the blood) of lucerastat. Safety of the concomitant administration of the two treatments will also be assessed.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Idorsia Pharmaceuticals Ltd.
• Treatments: Cimetidine

Criteria

Inclusion Criteria:

• Signed informed consent in the local language prior to any study-mandated procedure.

• Body mass index from 18.0 to 30.0 kg/m2 (inclusive) at Screening.

• Normal renal function confirmed by creatinine clearance ≥ 80 mL/min using Cockroft-Gault formula at Screening.

Exclusion Criteria:

• Known hypersensitivity to cimetidine, lucerastat, or drugs of the same class, or any of their excipients.

• History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).

• Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.